InvestorsHub Logo
Followers 51
Posts 3111
Boards Moderated 9
Alias Born 01/28/2001

Re: None

Wednesday, 05/15/2024 12:06:14 PM

Wednesday, May 15, 2024 12:06:14 PM

Post# of 50075
There are plans for clinical trials involving humans for KRM-II-81.

RespireRx Pharmaceuticals Inc. has reported that they are expanding the IND (Investigational New Drug) enabling studies in preparation to begin human studies. This is a significant step forward as it indicates that the compound has shown sufficient promise in preclinical studies to warrant further investigation in clinical settings.

The company has expressed excitement about the potential of KRM-II-81 to represent a breakthrough medication for pain, epilepsy, and other neuropsychiatric disorders, pending clinical validation. The advancement to human clinical trials is a critical phase in drug development, and it will provide more definitive evidence of the compound’s safety and efficacy in humans.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RSPI News